Upcoming · By Invitation

International Translational Oncology Exchange

Boston · May 13, 202614:00 – 16:00 ET
Learn more →
←Back to Expert Scholars
clinical / clinicalOvarian Cancer Advanced 2026

Anna Tinker

安娜·廷克尔

MD, FRCPC

🏢BC Cancer Vancouver Centre(不列颠哥伦比亚省癌症中心温哥华)🌐Canada

Medical Oncologist; Clinical Associate Professor, University of British Columbia肿瘤内科医生；不列颠哥伦比亚大学临床副教授

34
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Anna Tinker is a medical oncologist at BC Cancer Vancouver Centre and Clinical Associate Professor at the University of British Columbia, specializing in hereditary and sporadic ovarian cancer. She has led Canadian investigations into PARP inhibitor implementation, hereditary BRCA testing strategies, and molecular profiling for ovarian cancer. As a key voice in Canadian and international guidelines, she has advanced equitable access to PARP inhibitors and genetic testing in Canada.

Share:

🧪Research Fields 研究领域

PARP Inhibitor TherapyPARP抑制剂治疗
Hereditary BRCA Ovarian Cancer遗传性BRCA卵巢癌
Ovarian Cancer Genetic Testing卵巢癌基因检测
Gynecologic Oncology妇科肿瘤学
Canadian Ovarian Cancer Trials加拿大卵巢癌试验
Olaparib Niraparib Clinical Practice奥拉帕尼尼拉帕尼临床实践

🎓Key Contributions 主要贡献

Hereditary BRCA Testing in Ovarian Cancer in Canada

Championed universal hereditary cancer testing for all ovarian cancer patients in Canada, leading provincial and national initiatives to integrate BRCA and germline/somatic tumor testing into standard ovarian cancer care pathways.

PARP Inhibitor Implementation and Clinical Research

Led Canadian investigator-initiated and participation in international PARP inhibitor trials, generating real-world evidence and biomarker data for olaparib and niraparib in BC Cancer patient populations, informing Canadian treatment guidelines.

Representative Works 代表性著作

[1]

Germline and Somatic BRCA Testing in Ovarian Cancer: Canadian Recommendations

Current Oncology (2020)

Established evidence-based Canadian recommendations for universal BRCA testing in newly diagnosed ovarian cancer to guide PARP inhibitor eligibility and cascade genetic testing.

[2]

Real-World Outcomes of PARP Inhibitor Maintenance in Ovarian Cancer: BC Cancer Experience

Gynecologic Oncology (2023)

Real-world cohort analysis of olaparib and niraparib maintenance outcomes in BC Cancer patients, evaluating efficacy and toxicity in non-trial populations.

🏆Awards & Recognition 奖项与荣誉

🏆BC Cancer Excellence in Research Award
🏆Canadian Gynecologic Oncology Group Investigator Award
🏆UBC Department of Medicine Teaching Excellence Award

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Hope S. Rugo

University of California, San Francisco (UCSF)

Antibody-Drug Conjugates in Metastatic Breast CancerASCENT Trial and Sacituzumab Govitecan

Maryam B. Lustberg

Yale School of Medicine / Yale Cancer Center

Cardiotoxicity of CDK4/6 Inhibitors and Endocrine TherapyCancer Treatment-Related Cardiovascular Disease

Sara M. Tolaney

Dana-Farber Cancer Institute / Harvard Medical School

T-DM1 and KATHERINE Trial in Residual Disease After Neoadjuvant TherapyTrastuzumab Deruxtecan (T-DXd) and DESTINY-Breast Trials

Carlos H. Barrios

PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil

CDK4/6 Inhibitors in Low- and Middle-Income Countries (LMIC)Global Breast Cancer Clinical Trials and Access

关注 安娜·廷克尔 的研究动态

Follow Anna Tinker's research updates

留下邮箱，当我们发布与 Anna Tinker（BC Cancer Vancouver Centre）相关的新研究或访谈时，我们会通知你。

我们不会泄露你的信息，也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All ExpertsRead Research Insights